Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 19/20 | 0.63 |
| ▸ | TLR8 | Q9NR97 | 13/20 | 0.63 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16905105 | 0.99 | TLR7 (0.64) | TLR7TLR8NUDT1 | |
| SCHEMBL3863672 | 0.93 | TLR7 (0.53) | TLR7TLR8NUDT1 | |
| SCHEMBL543801 | 0.89 | TLR7 (0.65) | TLR7TLR8NUDT1 | |
| SCHEMBL2744557 | 0.86 | TLR7 (0.68) | TLR7TLR8NUDT1 | |
| SCHEMBL5750439 | 0.85 | TLR8 (0.56) | TLR7TLR8NUDT1 | |
| SCHEMBL18204188 | 0.85 | TLR7 (0.69) | TLR7TLR8NUDT1 | |
| SCHEMBL15872116 | 0.85 | TLR7 (0.59) | TLR7TLR8NUDT1 | |
| SCHEMBL544499 | 0.84 | TLR7 (0.41) | TLR7TLR8NUDT1 | |
| SCHEMBL3863883 | 0.83 | TLR7 (0.71) | TLR7TLR8NUDT1 | |
| SCHEMBL29371111 | 0.83 | TLR7 (0.71) | TLR7TLR8NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8961477-B2 | Delivery of immune response modifier compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2015-02-24 | — | — | US | claimed |
| EP-1651190-B1 | FORMULATIONS CONTAINING AN IMMUNE RESPONSE MODIFIER | 3M INNOVATIVE PROPERTIES CO (US) | 2012-09-19 | — | — | EP | claimed |
| EP-1651190-A4 | FORMULATIONS CONTAINING AN IMMUNE RESPONSE MODIFIER | 3M INNOVATIVE PROPERTIES CO (US) | 2009-07-15 | — | — | EP | claimed |
| US-20070292456-A1 | Formulations Containing an Immune Response Modifier | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-12-20 | — | — | US | claimed |
| EP-1651190-A2 | FORMULATIONS CONTAINING AN IMMUNE RESPONSE MODIFIER | 3M Innovative Properties Company (US) | 2006-05-03 | — | — | EP | claimed |
| WO-2005016275-A2 | FORMULATIONS CONTAINING AN IMMUNE RESPONSE MODIFIER | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-02-24 | — | — | WO | claimed |
| US-20170319712-A1 | METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSE | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2017-11-09 | — | — | US | disclosed |
| US-9801947-B2 | Methods and compositions for enhancing immune response | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2017-10-31 | — | — | US | disclosed |
| EP-3001990-A1 | A MIXTURE FOR TRANSDERMAL DELIVERY OF LOW& AND HIGH MOLECULAR WEIGHT COMPOUNDS | ORYXE (US) | 2016-04-06 | — | — | EP | disclosed |
| EP-1765310-B1 | A MIXTURE FOR TRANSDERMAL DELIVERY OF LOW AND HIGH MOLECULAR WEIGHT COMPOUNDS | ORYXE (US) | 2015-10-28 | — | — | EP | disclosed |
| US-8961477-B2 | Delivery of immune response modifier compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2015-02-24 | — | — | US | disclosed |
| US-20150044279-A1 | METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSE | 3M INNOVATIVE PROPERTIES CO (US) | 2015-02-12 | — | — | US | disclosed |
| US-20140200531-A1 | MIXTURE FOR TRANSDERMAL DELIVERY OF LOW AND HIGH MOLECULAR WEIGHT COMPOUNDS | JRX BIOTECHNOLOGY, INC. (US) | 2014-07-17 | — | — | US | disclosed |
| WO-2005020912-A2 | DELIVERY OF IMMUNE RESPONSE MODIFIER COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005016275-A2 | FORMULATIONS CONTAINING AN IMMUNE RESPONSE MODIFIER | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20040265351-A1 | Methods and compositions for enhancing immune response | 3M INNOVATIVE PROPERTIES COMPANY | 2004-12-30 | — | — | US | disclosed |
| US-20040258698-A1 | Delivery of immune response modifier compounds | 3M INNOVATIVE PROPERTIES COMPANY | 2004-12-23 | — | — | US | disclosed |
| WO-2004108072-A2 | DELIVERY OF IMMUNE RESPONSE MODIFIER COMPOUNDS USING METAL-CONTAINING PARTICULATE SUPPORT MATERIALS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-12-16 | — | — | WO | disclosed |
| WO-2004091500-A2 | DELIVERY OF IMMUNE RESPONSE MODIFIER COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-10-28 | — | — | WO | disclosed |
| US-20040202720-A1 | Delivery of immune response modifier compounds using metal-containing particulate support materials | 3M INNOVATIVE PROPERTIES COMPANY | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040265351-A1 | Methods and compositions for enhancing immune response | LRBA, CD69, MYD88 | TLR7 59/4885TLR8 60/4885NUDT1 3734/4885 |
| US-20070292456-A1 | Formulations Containing an Immune Response Modifier | IFNG, IRF3, ICOS | TLR7 18/4885TLR8 28/4885NUDT1 1398/4885 |
| US-20040258698-A1 | Delivery of immune response modifier compounds | MIF, IRF3, CLEC4M | TLR7 126/4885TLR8 51/4885NUDT1 4064/4885 |
| US-20150044279-A1 | METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSE | LRBA, CD69, MYD88 | TLR7 59/4885TLR8 60/4885NUDT1 3734/4885 |
| US-20170319712-A1 | METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSE | LRBA, CD69, MYD88 | TLR7 59/4885TLR8 60/4885NUDT1 3734/4885 |
| US-20040202720-A1 | Delivery of immune response modifier compounds using metal-containing particulate support materials | MIF, IRF3, IRF2BP2 | TLR7 131/4885TLR8 99/4885NUDT1 4048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.